DS
ACRS icon

David Shaw’s Aclaris Therapeutics ACRS Stock Holding History

David Shaw’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Sell
414,499
-486,305
-54% -$2.17M ﹤0.01% 3123
2026
Q1 		$3.38M Sell
900,804
-1,195,847
-57% -$4.03M ﹤0.01% 2483
2025
Q4 		$6.31M Sell
2,096,651
-276,575
-12% -$699K ﹤0.01% 2118
2025
Q3 		$4.51M Sell
2,373,226
-427,056
-15% -$745K ﹤0.01% 2316
2025
Q2 		$3.98M Sell
2,800,282
-144,230
-5% -$195K ﹤0.01% 2201
2025
Q1 		$4.51M Sell
2,944,512
-349,113
-11% -$745K ﹤0.01% 1974
2024
Q4 		$8.17M Sell
3,293,625
-78,224
-2% -$195K 0.01% 1626
2024
Q3 		$3.88M Buy
3,371,849
+51,643
+2% +$63.3K ﹤0.01% 2152
2024
Q2 		$3.65M Buy
3,320,206
+37,224
+1% +$43.7K ﹤0.01% 2100
2024
Q1 		$4.07M Buy
3,282,982
+1,343,972
+69% +$1.6M ﹤0.01% 2044
2023
Q4 		$2.04M Buy
1,939,010
+1,873,000
+2,837% +$5.71M ﹤0.01% 2649
2023
Q3 		$452K Buy
66,010
+37,087
+128% +$317K ﹤0.01% 3468
2023
Q2 		$300K Buy
+28,923
New +$262K ﹤0.01% 3597
2022
Q1 		– Sell
-22,864
Closed -$332K – 5479
2021
Q4 		$332K Sell
22,864
-40,758
-64% -$617K ﹤0.01% 4633
2021
Q3 		$1.15M Sell
63,622
-205,633
-76% -$3.3M ﹤0.01% 3497
2021
Q2 		$4.73M Buy
+269,255
New +$6.12M ﹤0.01% 2097
2020
Q1 		– Sell
-69,769
Closed -$132K – 3879
2019
Q4 		$132K Sell
69,769
-631,696
-90% -$1.05M ﹤0.01% 3855
2019
Q3 		$758K Buy
701,465
+32,206
+5% +$45.7K ﹤0.01% 2984
2019
Q2 		$1.47M Sell
669,259
-1,183,610
-64% -$6.45M ﹤0.01% 2452
2019
Q1 		$11.1M Sell
1,852,869
-425,495
-19% -$2.82M 0.01% 1042
2018
Q4 		$16.8M Buy
2,278,364
+950,781
+72% +$9.8M 0.02% 785
2018
Q3 		$19.3M Buy
1,327,583
+58,668
+5% +$1.01M 0.02% 789
2018
Q2 		$25.3M Buy
1,268,915
+30,629
+2% +$566K 0.03% 606
2018
Q1 		$21.7M Buy
1,238,286
+215,158
+21% +$4.56M 0.03% 624
2017
Q4 		$25.2M Buy
1,023,128
+1,010,970
+8,315% +$24.6M 0.03% 575
2017
Q3 		$314K Buy
+12,158
New +$326K ﹤0.01% 3122

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

David Shaw's ACRS Position: Q2 2026 in Review

David Shaw reduced its Aclaris Therapeutics (ACRS) stake by 54% in Q2 2026, selling an estimated $2.17M and leaving 414,499 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3123.

David Shaw first reported a position in ACRS in Q3 2017 and has held it in 26 quarters since. The position peaked at $25.3M in Q2 2018. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • David Shaw held 414,499 shares of Aclaris Therapeutics worth $2.19M as of Q2 2026.
  • David Shaw sold 486,305 Aclaris Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Aclaris Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3123 holding.
  • David Shaw first reported a position in Aclaris Therapeutics in Q3 2017 and has held it in 26 quarters since.
  • David Shaw's Aclaris Therapeutics position peaked at $25.3M in Q2 2018.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.